Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001382884 | SCV001581840 | pathogenic | Metachromatic leukodystrophy | 2020-06-01 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has been observed in combination with another ARSA variant in a family affected with metachromatic leukodystrophy (PMID: 20890085). This variant is also known as 1101+1G>T in the literature. This variant is not present in population databases (ExAC no frequency). This sequence change affects a donor splice site in intron 6 of the ARSA gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in ARSA are known to be pathogenic (PMID: 8962139, 10477432). For these reasons, this variant has been classified as Pathogenic. |